Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
2018
2014
Barnett, 2012, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet, 380, 37, 10.1016/S0140-6736(12)60240-2
Chudasama, 2020, Healthy lifestyle and life expectancy in people with multimorbidity in the UK Biobank: a longitudinal cohort study, PLoS Med, 17, 10.1371/journal.pmed.1003332
Marengoni, 2011, Aging with multimorbidity: a systematic review of the literature, Ageing Res Rev, 10, 430, 10.1016/j.arr.2011.03.003
Kingston, 2018, Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model, Age Ageing, 47, 374, 10.1093/ageing/afx201
Eslam, 2019, Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology, Nat Rev Gastroenterol Hepatol, 17, 40, 10.1038/s41575-019-0212-0
Shiha, 2021, Redefining fatty liver disease: an international patient perspective, Lancet Gastroenterol Hepatol, 6, 73, 10.1016/S2468-1253(20)30294-6
Eslam, 2020, The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, Hepatol Int, 14, 889, 10.1007/s12072-020-10094-2
Mendez-Sanchez, 2021, The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease, Lancet Gastroenterol Hepatol, 6, 65, 10.1016/S2468-1253(20)30340-X
Shiha, 2021, Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa, Lancet Gastroenterol Hepatol, 6, 57, 10.1016/S2468-1253(20)30213-2
Zheng, 2020, From NAFLD to MAFLD: a “redefining” moment for fatty liver disease, Chin Med J (Engl), 133, 2271, 10.1097/CM9.0000000000000981
Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367
2016, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease, Obes Facts, 9, 65, 10.1159/000443344
Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002/hep.20466
Fracanzani, 2008, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429
Lazarus, 2020, A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe, J Hepatol, 72, 14, 10.1016/j.jhep.2019.08.027
Lin, 2020, Comparison of MAFLD and NAFLD diagnostic criteria in real world, Liver Int, 40, 2082, 10.1111/liv.14548
Yamamura, 2020, MAFLD identifies patients with significant hepatic fibrosis better than NAFLD, Liver Int, 40, 3018, 10.1111/liv.14675
Niriella, 2021, Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study, PLoS One, 16, 10.1371/journal.pone.0245762
Lee, 2020, Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study, Clin Gastroenterol Hepatol
Cleveland, 2019, Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study, J Gen Intern Med, 34, 2772, 10.1007/s11606-019-05340-9
Singh, 2020, Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort, Dig Dis Sci, 65, 978, 10.1007/s10620-019-05700-9
Zhang, 2019, Awareness and knowledge of nonalcoholic fatty liver disease among office employees in Beijing, China, Dig Dis Sci, 64, 708, 10.1007/s10620-018-5389-5
Wieland, 2015, Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk, J Clin Gastroenterol, 49, e6, 10.1097/MCG.0000000000000075
Le, 2019, Nonalcoholic fatty liver disease and renal function impairment: a cross-sectional population-based study on its relationship from 1999 to 2016, Hepatol Commun, 3, 1334, 10.1002/hep4.1408
Le, 2020, Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016, J Intern Med, 287, 711, 10.1111/joim.13035
Mlynarsky, 2016, Non-alcoholic fatty liver disease is not associated with a lower health perception, World J Gastroenterol, 22, 4362, 10.3748/wjg.v22.i17.4362
Stewart, 2012, Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease, Clin Liver Dis, 16, 615, 10.1016/j.cld.2012.05.007
Goh, 2016, Perceptions of non-alcoholic fatty liver disease - an Asian community-based study, Gastroenterol Rep (Oxf), 4, 131, 10.1093/gastro/gov047
Fouad, 2021, Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists, J Hepatol, 74, 1254, 10.1016/j.jhep.2020.12.035
Alem, 2021, Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback, J Hepatol, 74, 1261, 10.1016/j.jhep.2021.01.022
Spearman, 2021, The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD, J Hepatol, 74, 1256, 10.1016/j.jhep.2021.01.015
Clayton, 2021, From NAFLD to MAFLD: nurse and allied health perspective, Liver Int, 41, 683, 10.1111/liv.14788
Mantovani, 2020, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals, Gut, 70, 962, 10.1136/gutjnl-2020-322572
Yamazaki, 2015, Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes, Diabetes Care, 38, 1673, 10.2337/dc15-0140
Sung, 2013, Resolution of fatty liver and risk of incident diabetes, J Clin Endocrinol Metab, 98, 3637, 10.1210/jc.2013-1519
Afolabi, 2018, The relationship between glycaemic control and non-alcoholic fatty liver disease in Nigerian type 2 diabetic patients, J Natl Med Assoc, 110, 256
Targher, 2007, Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients, Diabetes Care, 30, 2119, 10.2337/dc07-0349
Mantovani, 2016, Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring, Diabetes Care, 39, 1416, 10.2337/dc16-0091
Targher, 2008, Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients, Diabetologia, 51, 444, 10.1007/s00125-007-0897-4
Mantovani, 2017, Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes, J Diabetes Complications, 31, 1021, 10.1016/j.jdiacomp.2017.01.024
Björkström, 2017, Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 15, 1461, 10.1016/j.cgh.2017.04.040
Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002/hep.26156
Dai, 2017, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis, Medicine (Baltimore), 96, 10.1097/MD.0000000000008179
Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021
Sarin, 2020, Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission, Lancet Gastroenterol Hepatol, 5, 167, 10.1016/S2468-1253(19)30342-5
Bazick, 2015, Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD, Diabetes Care, 38, 1347, 10.2337/dc14-1239
Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265
Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, 128, 2436, 10.1002/ijc.25797
de Marco, 1999, Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study, Diabetes Care, 22, 756, 10.2337/diacare.22.5.756
Bril, 2017, Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action, Diabetes Care, 40, 419, 10.2337/dc16-1787
Oni, 2013, A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?, Atherosclerosis, 230, 258, 10.1016/j.atherosclerosis.2013.07.052
Zhou, 2018, Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis, Eur J Gastroenterol Hepatol, 30, 631, 10.1097/MEG.0000000000001075
Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034
Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014
Henson, 2020, Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 51, 728, 10.1111/apt.15660
Zou, 2017, Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes, Intern Med J, 47, 1147, 10.1111/imj.13549
Abdeldyem, 2017, Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome, J Clin Lipidol, 11, 915, 10.1016/j.jacl.2017.04.115
López-Suárez, 2011, Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase, Eur J Gastroenterol Hepatol, 23, 1011, 10.1097/MEG.0b013e32834b8d52
Aneni, 2015, Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk, J Hypertens, 33, 1207, 10.1097/HJH.0000000000000532
Allen, 2019, The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity—a longitudinal cohort study, J Hepatol, 71, 1229, 10.1016/j.jhep.2019.08.018
Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, 10.1371/journal.pmed.1001680
Mantovani, 2018, Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis, Metabolism, 79, 64, 10.1016/j.metabol.2017.11.003
Park, 2019, Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study, J Intern Med, 286, 711, 10.1111/joim.12964
Vilar-Gomez, 2017, Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 45, 332, 10.1111/apt.13860
Chinnadurai, 2019, Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease, Nephrol Dial Transplant, 34, 449, 10.1093/ndt/gfx381
Chinnadurai, 2019, Increased risk for cardiovascular events in patients with diabetic kidney disease and non-alcoholic fatty liver disease, Nephron, 141, 24, 10.1159/000493472
Önnerhag, 2019, Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities, Clin Res Hepatol Gastroenterol, 43, 542, 10.1016/j.clinre.2019.02.004
Sperling, 2015, The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome, J Am Coll Cardiol, 66, 1050, 10.1016/j.jacc.2015.06.1328
Eslam, 2020, A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement, J Hepatol, 73, 202, 10.1016/j.jhep.2020.03.039
Daniels, 2019, ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis, Hepatology, 69, 1075, 10.1002/hep.30163
Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346
Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496
Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178
Siddiqui, 2019, Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, 156, 10.1016/j.cgh.2018.04.043
Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005
Dubé, 2011, Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide, Diabetologia, 54, 1147, 10.1007/s00125-011-2065-0
Saint-Pierre, 2018, Multidisciplinary collaboration in primary care: a systematic review, Fam Pract, 35, 132, 10.1093/fampra/cmx085
Vanfleteren, 2016, Management of chronic obstructive pulmonary disease beyond the lungs, Lancet Respir Med, 4, 911, 10.1016/S2213-2600(16)00097-7
Lim, 2014, Multidisciplinary approach to management of maternal asthma (MAMMA): a randomized controlled trial, Chest, 145, 1046, 10.1378/chest.13-2276
Marzolini, 2009, Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with severe schizophrenia: a multidisciplinary approach, Ment Health Phys Act, 2, 29, 10.1016/j.mhpa.2008.11.001
Kornelius, 2015, The diabetes shared care program and risks of cardiovascular events in type 2 diabetes, Am J Med, 128, 977, 10.1016/j.amjmed.2015.03.025
Montesi, 2016, Long-term weight loss maintenance for obesity: a multidisciplinary approach, Diabetes Metab Syndr Obes, 9, 37
Hamdy, 2017, Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study, BMJ Open Diabetes Res Care, 5, 10.1136/bmjdrc-2016-000259
Phelan, 2006, Are the eating and exercise habits of successful weight losers changing?, Obesity (Silver Spring), 14, 710, 10.1038/oby.2006.81
Thomas, 2014, Weight-loss maintenance for 10 years in the National Weight Control Registry, Am J Prev Med, 46, 17, 10.1016/j.amepre.2013.08.019
Caranti, 2007, Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents, Metabolism, 56, 1293, 10.1016/j.metabol.2007.05.004
Monzavi, 2006, Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention, Pediatrics, 117, e1111, 10.1542/peds.2005-1532
Balagopal, 2005, Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents, J Clin Endocrinol Metab, 90, 6192, 10.1210/jc.2004-2427
Chen, 2006, Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children, Metabolism, 55, 871, 10.1016/j.metabol.2006.03.001
Moolla, 2019, A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health, Frontline Gastroenterol, 10, 337, 10.1136/flgastro-2018-101155
Lee, 2019, Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 17, 1040, 10.1016/j.cgh.2018.10.017
Say, 2003, The importance of patient preferences in treatment decisions—challenges for doctors, BMJ, 327, 542, 10.1136/bmj.327.7414.542
Coulter, 2005, What do patients and the public want from primary care?, BMJ, 331, 1199, 10.1136/bmj.331.7526.1199
Coulter, 2007, Effectiveness of strategies for informing, educating, and involving patients, BMJ, 335, 24, 10.1136/bmj.39246.581169.80
Group, 2002, The Diabetes Prevention Program (DPP): description of lifestyle intervention, Diabetes Care, 25, 2165, 10.2337/diacare.25.12.2165
Eslam, 2019, Genetic insights for drug development in NAFLD, Trends Pharmacol Sci, 40, 506, 10.1016/j.tips.2019.05.002
Eslam, 2020, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease, Gastroenterology, 158, 1999, 10.1053/j.gastro.2019.11.312
Park, 2016, Adaptive randomization of neratinib in early breast cancer, N Engl J Med, 375, 11, 10.1056/NEJMoa1513750
Berry, 2015, The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research, Mol Oncol, 9, 951, 10.1016/j.molonc.2015.02.011
Vassal, 2015, Creating a unique, multi-stakeholder paediatric oncology platform to improve drug development for children and adolescents with cancer, Eur J Cancer, 51, 218, 10.1016/j.ejca.2014.10.029